Verapamil is a calcium-channel blocker used to treat several cardiovascular conditions. This article covers Verapamil, available as a generic medication and marketed under brand names such as Calan, Isoptin, and Verelan. In Hong Kong, Verapamil is a prescription-only product regulated by the Pharmacy and Poisons Board under the oversight of the Department of Health.
Verapamil belongs to the class of dihydropyridine calcium-channel blockers, although it has a stronger effect on the heart’s conduction system than most agents in that subclass. By binding to L-type calcium channels on vascular smooth muscle and cardiac myocytes, it reduces calcium influx during the plateau phase of the cardiac action potential. This leads to:
The onset of action after an oral dose is typically within 1-2 hours, with peak plasma concentrations occurring around 2-4 hours. Verapamil’s half-life ranges from 3 to 7 hours, depending on hepatic metabolism and renal excretion. Because the drug is metabolized primarily by the liver (CYP3A4), interactions with other substances that affect this enzyme are clinically important.
Verapamil is approved by regulatory agencies-including the Hong Kong Department of Health-for the following indications:
These uses are based on robust clinical trial data demonstrating efficacy in lowering blood pressure, reducing angina frequency, and controlling ventricular rate in atrial arrhythmias.
Some studies have evaluated Verapamil for conditions beyond its official labeling. When such off-label applications have sufficient peer-reviewed evidence, they are presented with a clear disclaimer.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment. Verapamil’s safety profile must be carefully considered before prescribing for these indications.
If specific interaction data are unavailable: Patients should inform their healthcare provider of all medicines, supplements, and herbal products before starting Verapamil.
All dosing must be individualized by a prescribing clinician.
Regular follow-up with a healthcare provider is essential for dose adjustments and safety monitoring.
This article provides educational information about Verapamil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Verapamil can interact with statins that are metabolized by CYP3A4 (e.g., simvastatin, lovastatin), potentially increasing statin concentrations and the risk of muscle toxicity. It is advisable to discuss dose adjustments or alternative statins with your prescriber.
Dizziness is a common early side effect due to blood-pressure lowering. Sit or lie down until it passes, avoid sudden standing, and inform your clinician if the sensation persists or worsens.
Brand-specific tablets such as Calan often bear a numeric imprint (e.g., “40” or “120”) and are typically white or off-white. Generic versions may differ in shape or imprint; always verify the product with your pharmacist.
Verapamil is not a controlled substance and does not appear on standard occupational drug-screening panels. However, disclose all prescribed medications if a comprehensive test is requested.
Yes, provided the medication is in its original labeled container, you carry a copy of the prescription, and you comply with Hong Kong’s import regulations (generally allowing a 30-day supply for personal use).
Verapamil does not have the bronchoconstrictive effects associated with non-selective beta-blockers, making it a reasonable option for hypertensive patients who also have asthma, pending individual assessment.
Verapamil has a stronger effect on cardiac conduction and contractility, whereas amlodipine primarily causes peripheral vasodilation with minimal impact on heart rate. Choice of agent depends on the specific cardiovascular condition being treated.
Blood-pressure reduction can be observed within a few days, but the full therapeutic effect may take 2-4 weeks as the dosage is titrated to the optimal level.
Yes, an extended-release formulation exists (often marketed as Verelan SR). It provides a once-daily dose, resulting in steadier blood levels and potentially fewer peaks and troughs compared with the immediate-release tablet taken multiple times daily.
Grapefruit juice inhibits CYP3A4, the enzyme that metabolizes Verapamil, leading to higher drug concentrations and an increased chance of hypotension or bradycardia. Patients are advised to avoid large amounts of grapefruit products while on Verapamil.
